Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03653507
Other study ID # 8951-CL-0302
Secondary ID 2018-000519-26CT
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date November 28, 2018
Est. completion date March 31, 2025

Study information

Verified date May 2024
Source Astellas Pharma Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as first-line treatment) as measured by Progression Free Survival (PFS). This study will also evaluate efficacy, physical function, safety, and tolerability of zolbetuximab, as well as its effects on quality of life. Pharmacokinetics (PK) of zolbetuximab and the immunogenicity profile of zolbetuximab will be evaluated as well.


Description:

The study consists of the following periods: screening; treatment; post-treatment follow up, safety follow up, long term and survival follow-up. After the marketing approval in Japan on 26 Mar 2024, this study continued as "post marketing clinical study" in Japan. In the rest of the countries which participated in this study, this study continued as clinical study.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 507
Est. completion date March 31, 2025
Est. primary completion date October 25, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - A female subject is eligible to participate if she is not pregnant (negative serum pregnancy test at screening; female subjects with elevated serum beta human chorionic gonadotropin (ßhCG) and a demonstrated non-pregnant status through additional testing are eligible) and at least 1 of the following conditions applies: - Not a woman of childbearing potential (WOCBP) OR - WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for 9 months after the final administration of oxaliplatin and 6 months after the final administration of all other study drugs. - Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 6 months after the final study treatment administration. - Female subject must not donate ova starting at screening and throughout the study period, and for 9 months after the final administration of oxaliplatin and 6 months after the final administration of all other study drugs. - A male subject with female partner(s) of childbearing potential: - must agree to use contraception during the treatment period and for 6 months after the final study treatment administration. - A male subject must not donate sperm during the treatment period and for 6 months after the final study treatment administration. - Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 6 months after the final study treatment administration. - Subject has histologically confirmed diagnosis of Gastric or GEJ adenocarcinoma. - Subject has radiologically confirmed locally advanced unresectable or metastatic disease within 28 days prior to randomization. - Subject has radiologically evaluable disease (measurable and/or non-measurable disease according to RECIST 1.1), per local assessment, = 28 days prior to randomization. For subjects with only 1 evaluable lesion and prior radiotherapy = 3 months before randomization, the lesion must either be outside the field of prior radiotherapy or have documented progression following radiation therapy. - Subject's tumor expresses CLDN18.2 in = 75% of tumor cells demonstrating moderate to strong membranous staining as determined by central IHC testing. - Subject has a HER2-negative tumor as determined by local or central testing on a gastric or GEJ tumor specimen. (Unique to China: Subject has a known HER2-negative gastric or GEJ tumor.) - Subject has ECOG performance status 0 or 1. - Subject has predicted life expectancy = 12 weeks. - Subject must meet all of the following criteria based on the centrally or locally analyzed laboratory tests collected within 14 days prior to randomization. In the case of multiple sample collections within this period, the most recent sample collection with available results should be used to determine eligibility. - Hemoglobin (Hb) = 9 g/dl. Subjects requiring transfusions are eligible if they have a post-transfusion Hgb = 9 g/dL. - Absolute Neutrophil Count (ANC) = 1.5x10^9/L - Platelets = 100x10^9/L - Albumin = 2.5 g/dL - Total Bilirubin = 1.5 x upper limit of normal (ULN) without liver metastases (or < 3.0 x ULN if liver metastases are present) - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 x ULN without liver metastases (or = 5 x ULN if liver metastases are present) - Estimated creatinine clearance = 30 mL/min - Prothrombin time/international normalized ratio (PT/INR) and partial thromboplastin time (PTT) = 1.5 x ULN (except for subjects receiving anticoagulation therapy) Exclusion Criteria: - Subject has received prior systemic chemotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. However, subject may have received either neo-adjuvant or adjuvant chemotherapy, immunotherapy or other systemic anticancer therapies as long as it was completed at least 6 months prior to randomization. - Subject has received radiotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma = 14 days prior to randomization and has not recovered from any related toxicity. - Subject has received treatment with herbal medications or other treatments that have known antitumor activity within 28 days prior to randomization. - Subject has received systemic immunosuppressive therapy, including systemic corticosteroids within 14 days prior to randomization. Subjects using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day of prednisone), receiving a single dose of systemic corticosteroids or receiving systemic corticosteroids as premedication for radiologic imaging contrast use are allowed. - Subject has received other investigational agents or devices within 28 days prior to randomization. - Subject has prior severe allergic reaction or intolerance to known ingredients of zolbetuximab or other monoclonal antibodies, including humanized or chimeric antibodies. - Subject has known immediate or delayed hypersensitivity, intolerance or contraindication to any component of study treatment. - Subject has prior severe allergic reaction or intolerance to any component of CAPOX. - Subject has known dihydropyrimidine dehydrogenase (DPD) deficiency. - Subject has a complete gastric outlet syndrome or a partial gastric outlet syndrome with persistent/recurrent vomiting. - Subject has significant gastric bleeding and/or untreated gastric ulcers that exclude the subject from participation. - Subject has a known history of a positive test for human immunodeficiency virus (HIV) infection or known active hepatitis B (positive hepatitis B surface antigen (HBs Ag)) or C infection. NOTE: Screening for these infections should be conducted per local requirements. - For subjects who are negative for HBs Ag, but hepatitis B core antibody (HBc Ab) positive, an HB deoxyribonucleic acid (DNA) test will be performed and if positive, the subject will be excluded. - Subjects with positive hepatitis C virus (HCV) serology, but negative HCV ribonucleic acid (RNA) test are eligible. - Subjects treated for HCV with undetectable viral load results are eligible. - Subject has an active autoimmune disease that has required systemic treatment within the past 3 months prior to randomization. - Subject has active infection requiring systemic therapy that has not completely resolved within 7 days prior to randomization. - Subject has significant cardiovascular disease, including any of the following: - Congestive heart failure (defined as New York Heart Association Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, stenting, coronary artery bypass graft, cerebrovascular accident (CVA) or hypertensive crisis within 6 months prior to randomization. - History of clinically significant ventricular arrhythmias (i.e., sustained ventricular tachycardia, ventricular fibrillation or Torsades de Pointes - QTc interval > 450 msec for male subjects; QTc interval > 470 msec for female subjects - History or family history of congenital long QT syndrome - Cardiac arrhythmias requiring anti-arrhythmic medications (Subject with rate controlled atrial fibrillation for > 1 month prior to randomization are eligible). - Subject has a history of central nervous system (CNS) metastases and/or carcinomatous meningitis from gastric/GEJ cancer.. - Subject has known peripheral sensory neuropathy > grade 1 unless the absence of deep tendon reflexes is the sole neurological abnormality. - Subject has had a major surgical procedure = 28 days prior to randomization. - Subject is without complete recovery from a major surgical procedure = 14 days prior to randomization. - Subject has psychiatric illness or social situations that would preclude study compliance. - Subject has another malignancy for which treatment is required. - Subject has any concurrent disease, infection, or co-morbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data.

Study Design


Related Conditions & MeSH terms

  • Adenocarcinoma
  • Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
  • Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
  • Metastatic Gastric Adenocarcinoma or Cancer
  • Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

Intervention

Drug:
zolbetuximab
Zolbetuximab will be administered as a minimum 2-hour IV infusion.
oxaliplatin
Oxaliplatin will be administered as a 2-hour IV infusion.
capecitabine
Capecitabine will be administered orally twice daily (bid).
placebo
Placebo will be administered as a minimum 2-hour IV infusion.

Locations

Country Name City State
Argentina Site AR54009 Buenos Aires
Argentina Site AR54006 Pergamino
Argentina Site AR54001 San Miguel De Tucuman
Argentina Site AR54004 San Miguel de Tucumán
Argentina Site AR54003 Viedma
Canada Site CA15004 Calgary
Canada Site CA15003 Chicoutimi Quebec
Canada Site CA15002 Rimouski Quebec
China Site CN86044 Baoding
China Site CN86035 Beijing
China Site CN86050 Beijing
China Site CN86025 Bengbu
China Site CN86002 Changchun
China Site CN86049 Changchun
China Site CN86053 Changchun
China Site CN86029 Changsha Hunan
China Site CN86021 Changzhou
China Site CN86039 Chengdu
China Site CN86052 Dalian
China Site CN86054 Dalian
China Site CN86015 Fuzhou
China Site CN86034 Fuzhou Fujian
China Site CN86037 Fuzhou Fujian
China Site CN86001 Guangzhou
China Site CN86042 Guangzhou
China Site CN86051 Haebrin
China Site CN86032 Haikou Hainan
China Site CN86007 Hangzhou Zhejiang
China Site CN86036 Hangzhou
China Site CN86043 Hengyang Hunan
China Site CN86038 Linyi
China Site CN86016 Nanjing
China Site CN86045 Nanning
China Site CN86014 Shanghai
China Site CN86026 Shantou
China Site CN86047 Shenyang
China Site CN86017 Shijiazhuang
China Site CN86027 Suzhou Jiangsu
China Site CN86009 Tianjin
China Site CN86040 Tianjin
China Site CN86031 Urumchi
China Site CN86004 Wuhan
China Site CN86005 Wuhan
China Site CN86046 Wuxi Jiangsu
China Site CN86013 Xi'an
China Site CN86030 Xiamen
China Site CN86011 Xuzhou
China Site CN86012 Zhengzhou Henan
China Site CN86024 Zhengzhou
Croatia Site HR38501 Varazdin
Croatia Site HR38502 Zagreb
Croatia Site HR38503 Zagreb
Greece Site GR30001 Athens
Greece Site GR30004 Heraklion
Greece Site GR30003 Larissa
Greece Site GR30005 Neo Faliro, Piraeus
Greece Site GR30007 Rio Patras
Greece Site GR30002 Thessaloniki
Greece Site GR30006 Thessaloniki
Ireland Site IE35301 Dublin
Ireland Site IE35302 Dublin
Japan Site JP81008 Akashi Hyogo
Japan Site JP81002 Chiba
Japan Site JP81007 Fukuoka-shi Fukuoka
Japan Site JP81006 Kashiwa
Japan Site JP81003 Kawasaki Kanagawa
Japan Site JP81004 Kita-gun Kagawa
Japan Site JP81012 Koto-ku
Japan Site JP81009 Matsuyama
Japan Site JP81010 Suita Osaka
Japan Site JP81011 Tsukiji
Japan Site JP81005 Utsunomiya Tochigi
Japan Site JP81001 Yokohama Kanagawa
Korea, Republic of Site KR82002 Daegu
Korea, Republic of Site KR82006 Goyang-si
Korea, Republic of Site KR82007 Gyeonggi-do
Korea, Republic of Site KR82014 Incheon
Korea, Republic of Site KR82008 Jeollanam-do
Korea, Republic of Site KR82010 Jeonju-si
Korea, Republic of Site KR82011 Seongnam-si
Korea, Republic of Site KR82001 Seoul
Korea, Republic of Site KR82003 Seoul
Korea, Republic of Site KR82012 Seoul
Korea, Republic of Site KR82013 Seoul
Korea, Republic of Site KR82015 Seoul
Korea, Republic of Site KR82009 Suwon
Malaysia Site MY60001 Georgetown
Malaysia Site MY60004 Kota Kinabalu
Malaysia Site MY60002 Kuala Lumpur
Malaysia Site MY60003 Kuala Lumpur
Malaysia Site MY60005 Kuala Lumpur
Netherlands Site NL31004 Groningen
Netherlands Site NL31003 Tilburg
Portugal Site PT35109 Braga
Portugal Site PT35110 Coimbra
Portugal Site PT35111 Guimaraes
Portugal Site PT35102 Lisboa
Portugal Site PT35106 Lisboa
Portugal Site PT35105 Porto
Portugal Site PT35108 Porto
Portugal Site PT35104 Santa Maria da Feira
Portugal Site PT35101 Setubal
Portugal Site PT35107 Vila Real
Romania Site RO40002 Bucharest
Romania Site RO40005 Cluj-Napoca
Romania Site RO40007 Cluj-Napoca
Romania Site RO40003 Craiova
Romania Site RO40004 Floresti
Romania Site RO40001 Iasi
Romania Site RO40006 Iasi
Romania Site RO40008 Timisoara
Spain Site ES34006 Barcelona
Spain Site ES34009 Barcelona
Spain Site ES34010 Barcelona
Spain Site ES34005 Coruña
Spain Site ES34001 Elche
Spain Site ES34002 Madrid
Spain Site ES34003 Madrid
Spain Site ES34008 Madrid
Spain Site ES34013 Madrid
Spain Site ES34011 Malaga
Spain Site ES34004 Pamplona
Spain Site ES34007 Valencia
Spain Site ES34012 Valencia
Taiwan Site TW88602 Kaohsiung
Taiwan Site TW88603 Taichung
Taiwan Site TW88604 Taipei
Taiwan Site TW88605 Tianan
Thailand Site TH66002 Bangkok
Thailand Site TH66005 Bangkok
Thailand Site TH66007 Bangkok
Thailand Site TH66009 Bangkok
Thailand Site TH66011 Laksi
Thailand Site TH66001 Muang
Thailand Site TH66003 Muang
Thailand Site TH66006 Pathumthani
Thailand Site TH66010 Pathumwan
Thailand Site TH66004 Songkla
Thailand Site TH66008 Watthana
Turkey Site TR90003 Atakum
Turkey Site TR90004 Balcali
Turkey Site TR90012 Bornova
Turkey Site TR90001 Bursa
Turkey Site TR90002 Istanbul
Turkey Site TR90010 Istanbul
Turkey Site TR90015 Istanbul
Turkey Site TR90007 Konya
Turkey Site TR90013 Konyaalti
Turkey Site TR90011 Malatya
Turkey Site TR90008 Pendik Istanbul
United Kingdom Site GB44002 Bristol
United Kingdom Site GB44004 Cardiff Wales
United Kingdom Site GB44001 London
United Kingdom Site GB44005 Northwood
United States New Mexico Oncology Hematology Albuquerque New Mexico
United States Prisma Health Cancer Institute Boiling Springs South Carolina
United States Montefiore Medical Center (MMC) Bronx New York
United States Parkland Hospital Dallas Texas
United States University of Texas Southwestern Medical Center Dallas Texas
United States University of Kansas Cancer Center and Medical Pavilion Fairway Kansas
United States Houston Methodist Cancer Center and Institute of Academic Medicine - Oncology Houston Texas
United States Pacific Cancer Care Monterey California
United States Ochsner Clinic CCOP New Orleans Louisiana
United States Weill Cornell Medical College (WCMC) New York New York
United States Utah Cancer Specialist Salt Lake City Utah

Sponsors (1)

Lead Sponsor Collaborator
Astellas Pharma Global Development, Inc.

Countries where clinical trial is conducted

United States,  Argentina,  Canada,  China,  Croatia,  Greece,  Ireland,  Japan,  Korea, Republic of,  Malaysia,  Netherlands,  Portugal,  Romania,  Spain,  Taiwan,  Thailand,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression Free Survival (PFS) PFS is defined as the time from the date of randomization until the date of radiological progressive disease (per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 by Independent Review Committee (IRC)) or death from any cause, whichever is earliest. up to 13 months
Secondary Overall Survival (OS) OS is defined as the time from the date of randomization until the date of death from any cause. up to 23 months
Secondary Time to confirmed deterioration (TTCD) in participant-reported physical functioning and Global Health Status/Quality of Life (GHS/QoL) TTCD is measured by EORTC QLQ-C30 and QLQ-OG25 plus STO22 Belching subscale and defined as time to first confirmed deterioration; that is, time from randomization to first clinically meaningful deterioration that is confirmed at the next scheduled visit. Up to 16 months
Secondary Objective Response Rate (ORR) ORR is defined as the proportion of participants who have a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by Independent Review Committee (IRC) per RECIST 1.1. up to 13 months
Secondary Duration Of Response (DOR) DOR, defined as the time from the date of the first response (CR/PR) until the date of progressive disease as assessed by IRC per RECIST 1.1 or date of death from any cause, whichever is earliest. up to 13 months
Secondary Safety and tolerability assessed by adverse events (AEs) An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. up to 16 months
Secondary Number of participants with laboratory assessments abnormalities and or adverse events Number of participants with potentially clinically significant laboratory values. up to 14 months
Secondary Number of participants with vital signs abnormalities and or adverse events Number of participants with potentially clinically significant vital sign values. up to 14 months
Secondary Number of participants with electrocardiograms (ECG) abnormalities and or adverse events Number of participants with potentially clinically significant ECG values. up to 14 months
Secondary Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status abnormalities and or adverse events Number of participants with potentially clinically significant ECOG performance status values. ECOG grades 0-5, where 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair and 5 = Dead. up to 13 months
Secondary Health Related Quality of Life (HRQoL) measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC-QLQ-C30) EORTC-QLQ-C30 is a cancer-specific 30-item questionnaire. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change. up to 16 months
Secondary Health Related Quality of Life (HRQoL) measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Oesophago-Gastric Module 25 (QLQ-OG25) questionnaire plus EORTC-QLQ-STO22 Belching subscale The EORTC-QLQ-OG25 instrument evaluates Gastric and Gastroesophageal Junction (GEJ) cancer-specific symptoms such as stomach discomfort, difficulties eating and swallowing and indigestion. It is a 25-item questionnaire. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much". To ensure relevant symptoms are adequately covered two questions from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Stomach (EORTC-QLQ-STO22) instrument related to belching and bile or acid coming in your mouth will be asked following the OG25 questionnaire. Participants rate items on a 4 point scale, with 1 as "not at all" and 4 as "very much". The total and subscale scores from the OG25 and item scores from the STO22 items will be reported. up to 16 months
Secondary Health Related Quality of Life (HRQoL) measured by the Global Pain (GP) questionnaire The GP instrument is a single assessment of overall pain where 0 equals no pain and 10 equals extreme pain. Low pain scores are considered a better outcome than a high pain score. up to 16 months
Secondary Health Related Quality of Life (HRQoL) measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) questionnaire The EQ-5D-5L is a standardized instrument developed by the EuroQol Group for use as a generic, preference-based measure of health outcomes. The EQ-5D-5L is a 5-item self-reported measure of functioning and wellbeing, which assesses 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension comprises 5 levels (no problems, slight problems, moderate problems, severe problems, extreme problems). A unique EQ-5D-5L health state is defined by combining 1 level from each of the 5 dimensions. This questionnaire also records the respondent's self-rated health status on a vertical graduated (0 = the worst health a participant can imagine to 100 = the best health a participant can imagine) visual analogue scale. Responses to the 5 items will also be converted to a weighted health state index (utility score) based on values derived from general population samples. up to 16 months
Secondary Pharmacokinetics (PK) of zolbetuximab: Concentration Immediately Prior to Dosing at multiple dosing (Ctrough) Ctrough will be derived from the PK serum samples collected. up to 16 months
Secondary Number of anti-drug antibody (ADA) Positive Participants Immunogenicity will be measured by the number of participants that are ADA positive. up to 16 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03504397 - A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer Phase 3
Available NCT06048081 - Early Access Program for Zolbetuximab